Last reviewed · How we verify
ASP5541
ASP5541 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.
ASP5541 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation. Used for Inflammatory and autoimmune disorders (specific indications under investigation in phase 2).
At a glance
| Generic name | ASP5541 |
|---|---|
| Also known as | PRL-02 |
| Sponsor | Astellas Pharma Global Development, Inc. |
| Drug class | Complement C5a receptor antagonist |
| Target | C5a receptor (C5aR) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
ASP5541 blocks the C5a receptor on immune cells, preventing the binding of complement component C5a and thereby reducing complement-driven inflammatory responses. This mechanism is intended to modulate excessive immune activation in inflammatory and autoimmune conditions while preserving protective immunity.
Approved indications
- Inflammatory and autoimmune disorders (specific indications under investigation in phase 2)
Common side effects
Key clinical trials
- A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer (PHASE2)
- A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer (PHASE1)
- A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASP5541 CI brief — competitive landscape report
- ASP5541 updates RSS · CI watch RSS
- Astellas Pharma Global Development, Inc. portfolio CI